NASDAQ$GBIO
Generation Bio Co · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Generation Bio's Q3 2024 financial results were reported, highlighting a decrease in net loss compared to the same quarter last year and a strong cash position expected to fund operations into 2H 2027.
Generation Bio reported a net loss of $15.3 million for Q3 2024, an improvement compared to the $28.3 million net loss in Q3 2023. The company's cash, cash equivalents, and marketable securities totaled $199.8 million as of September 30, 2024, which is expected to fund operations into the second half of 2027.
- Cash balance of $199.8 million expected to fund operations into 2H 2027.
- R&D expenses decreased to $15.1 million compared to $21.9 million in Q3 2023.
- G&A expenses decreased to $9.2 million compared to $11.6 million in Q3 2023.
- Net loss improved to $15.3 million, or $0.23 per share, compared to $28.3 million, or $0.43 per share, in Q3 2023.
Headline financials
Revenue & EPS history
Generation Bio · Revenue · Quarterly
$7.55M
Revenue by segment
Generation Bio · $2.15M total across 1 segment · Q3 2023
- Collaboration revenue$2.15M—100.0%
Forward guidance
Generation Bio expects its cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditures into the second half of 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q3 2024
+3.8%
Avg return
Earnings day
+5.9%
Avg return
5 days after
+8.6%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+61.7%
Q2 2025
Best reaction
-19.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -3.3% | +11.0% | +2.7% | |
| Q2 2025 | +61.7% | +62.0% | +46.9% | |
| Q1 2025 | +4.5% | +0.4% | +4.0% | |
| Q4 2024 | -3.7% | -14.3% | -9.5% | |
| Q3 2024 | +8.7% | -0.5% | -40.8% | |
| Q2 2024 | -2.0% | -3.7% | -10.2% | |
| Q1 2024 | +18.4% | +16.4% | +1.9% | |
| Q4 2023 | +3.1% | +11.5% | +39.4% | |
| Q3 2023 | -1.7% | +7.7% | +46.2% | |
| Q2 2023 | -5.3% | -7.0% | +6.8% | |
| Q1 2023 | -5.0% | -2.7% | +0.4% | |
| Q4 2022 | -8.4% | -10.0% | +15.5% | |
| Q3 2022 | +12.2% | — | — | |
| Q2 2022 | +7.7% | — | — | |
| Q1 2022 | -19.7% | — | — | |
| Q4 2021 | +21.1% | — | — | |
| Q3 2021 | -1.5% | — | — | |
| Q2 2021 | -6.2% | — | — | |
| Q1 2021 | +0.3% | — | — | |
| Q4 2020 | -0.9% | — | — | |
| Q3 2020 | +8.5% | — | — | |
| Q4 2019 | -0.5% | — | — | |
| Q2 2020 | -0.5% | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro